Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 07:30 ET | Source: Immuneering Corporation

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
May 04, 2026 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
April 20, 2026 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
April 01, 2026 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas
March 17, 2026 16:35 ET | Source: Immuneering Corporation

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
March 06, 2026 07:45 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
December 17, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA
December 16, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
November 25, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025 16:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

In new data, MEK inhibitor PAS-004 shows monotherapy partial response, favorable PK and safety profile, supporting best-in-class potential for NF1-PN.